Published on
May 22, 2019
- 14:00 GMT
KAER Biotherapeutics Awarded NIH Grant to develop SUPRAER® Surfactant Aerosol Therapy for Neonatal Respiratory Distress
Respiratory distress is the single most important cause of mortality and morbidity in preterm infants and is caused by a deficiency of lung surfactant. SAN DIEGO, CA, USA, May 22, 2019 /EINPresswire.com/ -- KAER Biotherapeutics has received a Phase I …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Technology
...